Amgen Inc

NASDAQ:AMGNUnited States

Jun 5, 2024

Show headlines and story abstract

• AMGEN TO PRESENT AT GOLDMAN SACHS 45TH ANNUAL GLOBAL HEALTHCARE CONFERENCE, from 4:00PM ET on Wednesday Jun 05, 2024 by Dow Jones

  4:00PM ET on Wednesday Jun 05, 2024 by Dow Jones
  Companies Mentioned: AMGN
  
  AMGEN TO PRESENT AT GOLDMAN SACHS 45TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
  
  PR Newswire
  
  THOUSAND OAKS, Calif., June 5, 2024
  
  THOUSAND OAKS, Calif., June 5, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 45(th) Annual Global Healthcare Conference at 9:20 a.m. ET on Monday, June 10, 2024. Peter Griffith, executive vice president and chief financial officer at Amgen, and Jay Bradner, executive vice president of Research and Development and chief scientific officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.
  

• Amgen Says Phase 3 Trial of Potential Autoimmune Disease Treatment Meets Endpoints, from 9:57AM ET on Wednesday Jun 05, 2024 by MT Newswires

  9:57AM ET on Wednesday Jun 05, 2024 by MT Newswires
  Companies Mentioned: AMGN
  09:57 AM EDT, 06/05/2024 (MT Newswires) -- Amgen (AMGN) said Wednesday its phase 3 clinical trial evaluating Uplizna as a treatment for immunoglobulin G4-related disease, an autoimmune condition, met its primary and key secondary endpoints. The comp...

• DJ Amgen's Uplizna Hits Phase 3 Endpoints in IgG4-RD, from 9:28AM ET on Wednesday Jun 05, 2024 by Dow Jones

  9:28AM ET on Wednesday Jun 05, 2024 by Dow Jones
  Companies Mentioned: AMGN
  
  By Colin Kellaher
  
  Amgen on Wednesday said a late-stage study of its autoimmune drug Uplizna hit its key goals in the treatment of immunoglobulin G4-related disease, a chronic, immune-mediated disease known as IgG4-RD.
  

• AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA(R) (INEBILIZUMAB-CDON) FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE (IgG4-RD), from 9:00AM ET on Wednesday Jun 05, 2024 by Dow Jones

  9:00AM ET on Wednesday Jun 05, 2024 by Dow Jones
  Companies Mentioned: AMGN
  
  References
  1. Perugino, C. A., & Stone, J. H. (2020). IgG4-related disease: an update on pathophysiology and implications for clinical care. Nature Reviews Rheumatology, 16(12), 702--714. 2. Stone, J. H., Zen, Y., & Deshpande, V. (2012). IgG4-Related Disease. New England Journal of Medicine, 366(6), 539--551. 3. Floreani, A., Okazaki, K., Uchida, K., & Gershwin, M. E. (2021). IgG4-related disease: Changing epidemiology and new thoughts on a multisystem disease. Journal of Translational Autoimmunity, 4, 100074. 4. Wallace, Z. S., Mattoo, H., Mahajan, V. S., Kulikova, M., Lu, L., Deshpande, V., Choi, H. K., Pillai, S., & Stone, J. H. (2016). Predictors of disease relapse in IgG4-related disease following rituximab. Rheumatology, 55(6), 1000--1008. 5. Zhang, W., & Stone, J. H. (2019). Management of IgG4-related disease. The Lancet Rheumatology, 1(1), e55--e65. 6. Brito-Zerón, P., Bosch, X., Gandía, M., Soto Cárdenas, M.-J. , Ramos-Casals, M., & Stone, J. H. (2017, January 1). Chapter 22 (pages 399-410) - IgG4-Related Disease: Gastrointestinal Involvement (M. Ramos-Casals, M. Khamashta, P. Britó-Zeron, F. Atzeni, & J. R. Teixidor, Eds.). ScienceDirect; Elsevier. 7. Wolfson, A. R., & Hamilos, D. L. (2017). Recent advances in understanding and managing IgG4-related disease. F1000Research, 6, 185.